Cargando…
Expression and Clinical Correlation of PD-1/PD-L1 and VE1(BRAFp.V600E) in Pediatric Langerhans Cell Histiocytosis
BACKGROUND AND OBJECTIVES: Langerhans cell histiocytosis (LCH) is an inflammatory myeloid neoplasm with a wide spectrum of clinical presentations. Programmed Cell Death-1 (PD-1) receptor and its ligand (PD-L1) are overexpressed in LCH, but their clinical significance is unknown. We performed a clini...
Autores principales: | Tandon, Sneha, Weitzman, Sheila, Joyce, Brooklyn, Mcguire, Bryan, Stephens, Derek, Whitlock, James, Hawkins, Cynthia, Ngan, Bo Yee, Abla, Oussama |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università Cattolica del Sacro Cuore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171209/ https://www.ncbi.nlm.nih.gov/pubmed/37180201 http://dx.doi.org/10.4084/MJHID.2023.035 |
Ejemplares similares
-
HGG-39. Integrative analyses of BRAFp.v600e mutated gliomas: from epigenetic to metabolic characteristics
por: Lhermitte, Benoit, et al.
Publicado: (2022) -
Bisphosphonates in Langerhans Cell Histiocytosis: An International Retrospective Case Series
por: Chellapandian, Deepak, et al.
Publicado: (2016) -
Characterization of PD-1/PD-L1 immune checkpoint expression in the pathogenesis of musculoskeletal Langerhans cell histiocytosis: A retrospective study
por: Hashimoto, Kazuhiko, et al.
Publicado: (2021) -
Dabrafenib, alone or in combination with trametinib, in BRAF V600–mutated pediatric Langerhans cell histiocytosis
por: Whitlock, James A., et al.
Publicado: (2023) -
BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis
por: Prada Avella, Maria Camila, et al.
Publicado: (2020)